Comparison of the Hydrolysis and Esterification Methods for the Determination of Genotoxic 5-Chlorothiophene-2-Carbonyl Chloride in Rivaroxaban Using HPLC
暂无分享,去创建一个
[1] David Q. Liu,et al. Recent advances in trace analysis of pharmaceutical genotoxic impurities. , 2010, Journal of pharmaceutical and biomedical analysis.
[2] Nanduri V V S S Raman,et al. Sensitive derivatization methods for the determination of genotoxic impurities in drug substances using hyphenated techniques. , 2014, Journal of pharmaceutical and biomedical analysis.
[3] S. Magiera. Fast, simultaneous quantification of three novel cardiac drugs in human urine by MEPS-UHPLC-MS/MS for therapeutic drug monitoring. , 2013, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
[4] R. Investigators. Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study. , 2010, American heart journal.
[5] Jun Wang,et al. Ultra high performance liquid chromatography coupled with high resolution quantitation mass spectrometry method development and validation for determining genotoxic 2,5-dichlorobenzoyl chloride in MLN9708 drug substance. , 2014, Journal of pharmaceutical and biomedical analysis.
[6] K Jayasree,et al. A validated CE method for determining dimethylsulfate a carcinogen and chloroacetyl chloride a potential genotoxin at trace levels in drug substances. , 2012, Journal of pharmaceutical and biomedical analysis.
[7] M. Iqbal,et al. A validated high-throughput UHPLC-MS/MS assay for accurate determination of rivaroxaban in plasma sample , 2014, Journal of Thrombosis and Thrombolysis.
[8] J. Hulot,et al. Simultaneous determination of rivaroxaban and dabigatran levels in human plasma by high-performance liquid chromatography-tandem mass spectrometry. , 2014, Journal of pharmaceutical and biomedical analysis.
[9] A. Turpie. Rivaroxaban as an oral anticoagulant for stroke prevention in atrial fibrillation , 2014, Therapeutics and clinical risk management.
[10] Scott A. Miller,et al. Development and validation of a specific and sensitive GC-FID method for the determination of impurities in 5-chlorovaleroyl chloride. , 2010, Journal of pharmaceutical and biomedical analysis.
[11] G. Rohde. Determination of rivaroxaban--a novel, oral, direct Factor Xa inhibitor--in human plasma by high-performance liquid chromatography-tandem mass spectrometry. , 2008, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
[12] Ramakrishna Kuntamukkala,et al. Development and validation of a stability indicating LC-PDA-MS/MS method for separation, identification and characterization of process related and stress degradation products of rivaroxaban , 2014 .